Global AntiAsthmatics And COPD Drugs Market Analysis, Trends and Opportunities
Summary A new market study, titled “Global AntiAsthmatics
And COPD Drugs Market
Analysis, Trends and Opportunities ” has been featured on WiseGuyReports.
Reasons to Purchase
• Gain a truly global perspective
with the most comprehensive report available on this market covering 50+
geographies.
• Create regional and country
strategies on the basis of local data and analysis.
• Identify growth segments for
investment.
• Outperform competitors using
forecast data and the drivers and trends shaping the market.
• Understand customers based on the
latest market research findings.
• Benchmark performance against key
competitors.
• Utilize the relationships between
key data sets for superior strategizing.
• Suitable for supporting your
internal and external presentations with reliable high quality data and
analysis
• Report will be updated with the
latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest
growing market for the anti-asthmatics and copd drugs? How does the market
relate to the overall economy, demography and other similar markets? What
forces will shape the market going forward? The Anti-Asthmatics And COPD Drugs
Market Global Report from The Business Research Company answers all these
questions and many more.
The report covers market
characteristics, size and growth, segmentation, regional and country
breakdowns, competitive landscape, market shares, trends and strategies for
this market.
• The Market Characteristics section
of the report defines and explains the market.
• The Market Size section gives the
market size ($b) covering both the historic growth of the market and
forecasting the future. Drivers and restraints looks at the external factors
supporting and controlling the growth of the market.
• Market Segmentations break down
market into sub markets.
• The Regional and Country section
gives an analysis of the market in each geography and the size of the market by
geography and compares their historic and forecast growth. It covers all the
regions, key developed countries and major emerging markets. It draws
comparisons with country populations and economies to understand the importance
of the market by country and how this is changing.
• Competitive Landscape gives a
description of the competitive nature of the market, market shares, and a
description of the leading companies. Key financial deals which have shaped the
market in recent years are identified.
• The Trends and Strategies section
highlights the likely future developments in the market and suggests approaches
companies can take to exploit this.
Scope
Markets Covered: 1) By Drug Class:
Bronchodilators , Anti-inflammatory Drugs, Monoclonal Antibodies, Combination
Drugs 2) By End User: Asthma Patients, COPD Patients 3) By Distribution
Channel: Hospital Pharmacies , Private Clinics , Drug Stores , Retail
Pharmacies , E-Commerce
Companies Mentioned: Novartis AG,
Merck & Co, GlaxoSmithKline , Boehringer Ingelheim Gmbh, AstraZeneca
Countries: Australia, Brazil, China,
France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
Regions: Asia-Pacific, Western
Europe, Eastern Europe, North America, South America, Middle East, Africa
Time Series: Five years historic and
forecast.
Data Segmentations: country and
regional historic and forecast data, market share of competitors, market
segments.
Sourcing and Referencing: Data and
analysis throughout the report is sourced using end notes.
The anti-asthmatics and chronic
obstructive pulmonary disease (COPD) market consists of sales of
anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which
are used to relieve the frequency of acute attacks of asthma, emphysema,
chronic bronchitis, and nocturnal awakenings. The class of drugs includes
Bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination
drugs.
The global anti-asthmatics and copd
drugs market was valued at about $33.4 billion in 2018 and is expected to grow
to $42.01 billion at a CAGR of 5.9% through 2022.
North America was the largest region
in the anti-asthmatics and COPD drugs market in 2017.
Modifiable risk factors including
smoking, lack of physical exercise, and unhealthy eating habits drive the
Asthma and COPD drugs market. Even though there is a decreasing trend of
smoking prevalence globally, developing countries such as China, India,
Indonesia, and Nigeria among others have increasing smoking prevalence. For
instance, the number of tobacco smokers is set to increase by 24 million in
Indonesia and by 7 million in Nigeria from 2015 to 2025, and more than 40% of
global cigarette consumption is concentrated in China. Consumption of fats
including saturated fatty acids which is a risk factor for Asthma and COPD is
more in high income countries including USA and Europe. According to WHO, in
developed countries more than 35% of total energy requirement is derived from
fats when compared to direct alternatives to CFC Metered Dose Inhalers, but may
in many patients serve as a useful medication that could replace the need for a
particular CFC Metered Dose Inhaler. FDA will determine official alternatives
by using the criteria established through notice-and-comment rulemaking.
Major players in the market are
Novartis AG, Merck & Co, GlaxoSmithKline , Boehringer Ingelheim Gmbh and
AstraZeneca.
FOR MORE DETAILS :-https://www.wiseguyreports.com/reports/4588877antiasthmaticsandcopddrugsglobalmarketreport
About Us:
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and governments
around the globe.
Contact Us:
NORAH
TRENT
Ph: +16282580070
(US)
Ph: +44 2035002763 (UK)
Comments
Post a Comment